Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
Jeffrey Lawrence Schwartz, a partner at Bain Capital Investors and a director/10% owner of Kestra Medical Technologies, acquired 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts to one common share and the RSUs vest on 09/04/2026 subject to continued service. After the reported acquisition Mr. Schwartz beneficially owns 10,909 shares directly and 27,019,225 shares indirectly, the latter held by Bain Charger Holdings, L.P. and West Affum Holdings, L.P., with Bain Capital entities holding controlling interests. Mr. Schwartz disclaims beneficial ownership except to the extent of his pecuniary interest.
Elizabeth Kwo, a director of Kestra Medical Technologies, Ltd. (KMTS), was granted 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts into one common share and the award will vest on 09/04/2026 provided Ms. Kwo remains in service through that date. The Form 4 was filed as an individual filing and signed by an attorney-in-fact, Traci S. Umberger, on 09/08/2025. This disclosure reports a non-derivative equity grant to an insider rather than a market sale or open-market purchase; no option exercise, sale price, or cash consideration is reported.
Elizabeth Kwo, a director of Kestra Medical Technologies, Ltd. (KMTS), reported ownership of 10,909 restricted stock units (RSUs). The RSUs each convert into one common share and are scheduled to vest on 09/04/2026, subject to her continued service. The Form 3 was filed following an event on 09/03/2025 and is the initial statement disclosing her direct beneficial ownership of these non-derivative securities.
Kestra Medical Technologies, Ltd. held its 2025 annual general meeting of shareholders on September 3, 2025. A total of 48,835,102 common shares were voted in person or by proxy, representing approximately 95% of the 51,348,656 shares outstanding and entitled to vote as of July 7, 2025.
Shareholders elected Conor Hanley and Elizabeth Kwo as Class I directors to serve until the 2028 annual meeting and until their successors are duly elected and qualified. The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending April 30, 2026 was ratified. Shareholders also approved the company’s 2025 Employee Stock Purchase Plan.